Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by INmune Bio, Inc.

< Previous 1 2 Next >
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Announces $13.0 Million Registered Direct Offering
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. to Join Russell 3000® Index
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From INmune Bio, Inc.
Via GlobeNewswire
Tickers INMB
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.